Detalles de la búsqueda
1.
Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan.
Clin Infect Dis
; 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833593
2.
Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
Euro Surveill
; 29(17)2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38666403
3.
Integrated use of laboratory services for multiple infectious diseases in the WHO European Region during the COVID-19 pandemic and beyond.
Euro Surveill
; 27(29)2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35866437
4.
Impact of the COVID-19 pandemic on tuberculosis national reference laboratory services in the WHO European Region, March to November 2020.
Euro Surveill
; 26(24)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34142651
5.
Early COVID-19 pandemic's toll on tuberculosis services, WHO European Region, January to June 2020.
Euro Surveill
; 26(24)2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34142649
6.
Operational research as an instrument to address the critical gaps for effective treatment of tuberculosis in eastern Europe and central Asia.
Monaldi Arch Chest Dis
; 91(1)2021 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33470079
7.
Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study.
Monaldi Arch Chest Dis
; 91(1)2021 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33470087
8.
Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18.
Monaldi Arch Chest Dis
; 91(1)2021 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33470081
9.
Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Monaldi Arch Chest Dis
; 91(1)2021 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33470080
10.
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Clin Infect Dis
; 71(2): 415-418, 2020 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31676905
11.
Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.
Eur Respir J
; 53(6)2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31023852
12.
Screening for tuberculosis among migrants in Europe: harmonising approaches during a humanitarian crisis?
Eur Respir J
; 62(4)2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37827550
13.
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
Eur Respir J
; 60(2)2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35777762
14.
Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB.
Clin Infect Dis
; 63(2): 214-20, 2016 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27161772
15.
What is behind programmatic treatment outcome definitions for tuberculosis?
Eur Respir J
; 56(1)2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32703821
16.
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.
Clin Infect Dis
; 59(1): 9-15, 2014 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24729493
17.
PASS to End TB in Europe: Accelerated efforts on prevention and systematic screening to end tuberculosis in the WHO European Region by 2030.
Int J Infect Dis
; 141S: 106980, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38403111
18.
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Lancet Infect Dis
; 2024 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38880112
19.
National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region.
J Travel Med
; 30(1)2023 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36426801
20.
Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study.
Int J Environ Res Public Health
; 19(7)2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35410048